Task-Specific Training vs. Yoga (With and Without Perturbation) for Balance and Leg Strength in Older Adults
NCT06875388, Not applicable, Active not recruiting, Shifa Tameer-e-Millat University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Task-Specific Training vs. Yoga (With and Without Perturbation) for Balance and Leg Strength in Older Adults | ClinicalTrials.gov |
| NCT number | NCT06875388 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 200 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Shifa Tameer-e-Millat University | ClinicalTrials.gov |
| Conditions | Cognitive Functioning of Healthy Individuals, Balance, Strength, Muscle, Quality of Life (QOL) | ClinicalTrials.gov |
| Interventions | Task specific Training, Specific Yoga Poses, Tasl specific Training with perturbation, Specific yoga poses with perturbation | ClinicalTrials.gov |
| First posted | 2025-03-13 | ClinicalTrials.gov |
| Last updated | 2025-03-26 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Manual Release from Lean (MRFL) Test: | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | This methodology assesses balance recovery using MFRL and CRFL-inspired tests. Participants wear a safety harness and stand on a standardized foot placement template (17cm heel distance, 14° angle). Trained personnel and a cushioned mat ensure safety. The test involves a controlled forward lean (≤15°) with sudden release by an administrator. A practice trial familiarizes participants before three test trials. Balance recovery is assessed qualitatively (e.g., stepping, arm use) and quantitatively (distance covered, time). Core muscles, including glutes, hamstrings, and abdominals, stabilize movement. Safety measures include verbal cues, secure harness checks, and moderate perturbations. | ClinicalTrials.gov |
| Primary | Mini Balance Evaluation Systems Test (Mini-BESTest) | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | The Mini-BESTest is a clinical tool assessing dynamic balance and postural control in individuals with neurological conditions, older adults, and those recovering from injuries. It consists of 14 items across four categories: Anticipatory Postural Adjustments, Reactive Postural Control, Sensory Orientation, and Dynamic Gait. Each item is scored from 0-2, with a maximum score of 28; ≤19 indicates a high fall risk. The test is more sensitive than traditional balance assessments and helps guide rehabilitation by identifying specific impairments and tracking progress. It is widely used in neurology, geriatrics, and rehabilitation for fall prevention and treatment planning. | ClinicalTrials.gov |
| Primary | Manual Muscle Testing (MMT): | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | Manual Muscle Testing (MMT) is a clinical assessment used to evaluate muscle strength and function by applying resistance against a patient's voluntary movement. It helps diagnose neuromuscular conditions, monitor progress, and guide rehabilitation. MMT grades muscle strength on a 0-5 scale: 0 (no contraction), 1 (visible contraction, no movement), 2 (movement without gravity), 3 (movement against gravity), 4 (movement against moderate resistance), and 5 (normal strength). Testing involves positioning the patient, stabilizing the joint, and applying resistance while observing for compensatory movements. MMT is widely used in physical therapy, neurology, and sports medicine to assess muscular imbalances, nerve injuries, and overall functional capacity. Though subjective, when combined with functional tests and dynamometry, it provides valuable insight into muscle performance, aiding in treatment planning and progress tracking for various musculoskeletal and neurological conditions. | ClinicalTrials.gov |
| Primary | 30- secs sit to stand test | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | The 30-Second Sit-to-Stand Test (30s STS) assesses lower body strength, endurance, and balance, especially in older adults and those with mobility impairments. Participants repeatedly stand from a sturdy chair for 30 seconds, with total repetitions recorded. It evaluates leg strength and functional power, essential for daily activities and fall prevention. Scores ≤12 indicate increased fall risk. Key muscles involved include the quadriceps, gluteus maximus, hamstrings, calves, and core. The test is widely used in clinical and research settings to track rehabilitation progress and guide fall prevention strategies. Its simplicity makes it a reliable tool for identifying mobility decline and designing targeted interventions. | ClinicalTrials.gov |
| Primary | Mini Mental State Examination (MMSE) | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | used For mental status and cognitive function The Mini-Mental State Examination (MMSE) scores range from 0 to 30, with higher scores indicating better cognitive function; a score of 24 or higher is generally considered normal, while scores below 24 may suggest cognitive impairment. Here's a more detailed breakdown of the scoring guide and what the scores mean: Scoring: Maximum Score: 30 Normal: 24 or higher Mild Cognitive Impairment: 18-23 Moderate Cognitive Impairment: 10-17 Severe Cognitive Impairment: 0-9 \<23 is generally accepted as indicating cognitive impairment Areas Assessed: The MMSE assesses five key areas of cognitive function: Orientation: (Time and Place) Registration: (Repeating named prompts) Attention and Calculation: (Serial sevens or spelling "world" backward) Recall: (Registration recall) Language: (Naming a pencil and a watch) | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life Brief Version ( WHOQOL-BREF ) | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, an average of 3 months | For assessing the quality of life: 1. A shorter, 26-item version of the original 100-item WHOQOL questionnaire. It assesses four domains of quality of life: physical health, psychological health, social relationships, and environment. 2. It is a self-report questionnaire, meaning individuals answer the questions themselves. 3. Each of the 26 items in the WHOQOL-BREF is scored on a 5-level scale(e.g., 1- 5), allowing for the calculation of domain-specific and overall quality-of-life scores. 4. Higher scores generally indicate a better quality of life. | ClinicalTrials.gov |
| Secondary | The Barthel Scale/Index (BI) | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, at an average of 3 months | Used for assessing functional independence in activities of daily living (ADLs) with scores ranging from 0 to 100 The Barthel Index is a 100-point scale, with each activity assigned a numeric value based on the level of assistance needed. Total Score: The total score is calculated by summing the scores for each of the 10 ADLs. Higher Scores: Indicate greater independence. Lower Scores: Indicate less independence. Interpretation: 0-20: Total dependency. 21-60: Severe dependency. 61-90: Moderate dependency. 91-99: Slight dependency. 100: Total independence. | ClinicalTrials.gov |
| Secondary | Mini Stroop test | Outcome measure will be assessed at baseline as a pre-intervention procedure. 2nd time point will be 'immediately after the six-week intervention.' Third time point will be 'through study completion, at an average of 3 months | The Mini Stroop Test is a cognitive assessment measuring inhibition, cognitive flexibility, and attentional control. It requires individuals to name the ink color of printed words while ignoring the word itself, assessing the ability to override automatic reading responses. Performance is evaluated based on response time and error rate, with longer times and higher errors indicating cognitive control difficulties. It primarily assesses the prefrontal and anterior cingulate cortex, involved in executive functions like attention and inhibition. Poor performance may indicate issues with cognitive flexibility, inhibitory control, or executive dysfunction seen in ADHD, brain injuries, and frontal lobe disorders. Its simplicity makes it useful in clinical and research settings for identifying cognitive impairments and understanding brain-behavior relationships. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)